Rezafungin plasma concentrations in patients with or without extracorporal treatments (ECMO ± RRT)

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519789-37-00

Enrollment

Registered

2025-04-14

Start date

2025-04-16

Completion date

Unknown

Last updated

2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive candidiasis

Brief summary

Clearance (CL), Volume of Distribution (Vd), Half-Life (t½), Absorption Rate Constant (Ka), Bioavailability (F), Maximum Concentration (Cmax), Time to Maximum Concentration (Tmax), Area Under the Curve (AUC), Elimination Rate Constant (Ke)

Detailed description

Difference in Rezafunding plasma concentration according to additional extracorporal circuits (RRT, Hemoperfusion), Difference of Rezafunding plasma concentration according to body-mass index and gender, Side effects of Rezafungin treatment (As defined by the treating physician), Rate of Rezafungin discontinuation and reasons for cessation

Interventions

DRUGREZZAYO 200 mg powder for concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Clearance (CL), Volume of Distribution (Vd), Half-Life (t½), Absorption Rate Constant (Ka), Bioavailability (F), Maximum Concentration (Cmax), Time to Maximum Concentration (Tmax), Area Under the Curve (AUC), Elimination Rate Constant (Ke)	—

Secondary

Measure	Time frame
Difference in Rezafunding plasma concentration according to additional extracorporal circuits (RRT, Hemoperfusion), Difference of Rezafunding plasma concentration according to body-mass index and gender, Side effects of Rezafungin treatment (As defined by the treating physician), Rate of Rezafungin discontinuation and reasons for cessation	—

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026